These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 6406715)
1. Sudden death induced by intracoronary platelet aggregation. Yamazaki H; Isohisa I; Tanoue K Jpn Circ J; 1983 May; 47(5):596-607. PubMed ID: 6406715 [TBL] [Abstract][Full Text] [Related]
2. The effect of a thromboxane synthetase inhibitor, OKY-046, on urinary excretion of immunoreactive thromboxane B2 and 6-keto-prostaglandin F1 alpha in patients with ischemic cerebrovascular disease. Uyama O; Nagatsuka K; Nakabayashi S; Isaka Y; Yoneda S; Kimura K; Abe H Stroke; 1985; 16(2):241-4. PubMed ID: 3883580 [TBL] [Abstract][Full Text] [Related]
3. Reduction of prostacyclin synthesis as a possible cause of transient flow reduction in a partially constricted canine coronary artery. Tada M; Esumi K; Yamagishi M; Kuzuya T; Matsuda H; Abe H; Uchida Y; Murao S J Mol Cell Cardiol; 1984 Dec; 16(12):1137-49. PubMed ID: 6398370 [TBL] [Abstract][Full Text] [Related]
4. Arachidonic acid induced platelet aggregation and thromboxane formation is inhibited by OKY-1581. Uotila P; Matintalo M; Dahl ML Prostaglandins Leukot Med; 1983 Nov; 12(3):299-303. PubMed ID: 6419237 [TBL] [Abstract][Full Text] [Related]
5. Protective actions of a new thromboxane synthetase inhibitor in arachidonate induced sudden death. Edmonds LC; Lefer AM Life Sci; 1984 Oct; 35(17):1763-8. PubMed ID: 6434893 [TBL] [Abstract][Full Text] [Related]
6. Intravenous infusion of a selective inhibitor of thromboxane A2 synthetase in man: influence on thromboxane B2 and 6-keto-prostaglandin F1 alpha levels and platelet aggregation. Yui Y; Hattori R; Takatsu Y; Nakajima H; Wakabayashi A; Kawai C; Kayama N; Hiraku S; Inagawa T; Tsubojima M Circulation; 1984 Oct; 70(4):599-605. PubMed ID: 6434196 [TBL] [Abstract][Full Text] [Related]
7. Effect of vacuum curettage on the concentrations of plasma 6-keto-prostaglandin F1 alpha and serum thromboxane B2. Ylikorkala O; Mäkilä UM; Viinikka L Br J Obstet Gynaecol; 1983 Mar; 90(3):251-4. PubMed ID: 6338904 [TBL] [Abstract][Full Text] [Related]
8. Effects of a selective thromboxane synthetase inhibitor (OKY-046) in patients with coronary artery disease during exercise. Shikano M; Ito T; Ogawa K; Satake T Jpn Heart J; 1987 Sep; 28(5):663-74. PubMed ID: 3323562 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of arachidonic acid induced-aggregation of rabbit platelets with CV-4151 (isbogrel), a selective thromboxane A2 (TXA2) synthase inhibitor: modulation of the antiplatelet action and prostanoid metabolism by rat aortic rings. Terashita Z; Imura Y; Nishikawa K J Lipid Mediat Cell Signal; 1996 Jan; 13(1):1-8. PubMed ID: 8821806 [TBL] [Abstract][Full Text] [Related]
10. Effect of the infusion of OKY-046, a thromboxane A2 synthase inhibitor, on urinary metabolites of prostacyclin and thromboxane A2 in healthy human subjects. Morio H; Hirai A; Terano T; Tamura Y; Yoshida S Thromb Haemost; 1993 Mar; 69(3):276-81. PubMed ID: 8470052 [TBL] [Abstract][Full Text] [Related]
11. [Plasma level and effects of thromboxane A2 and 6-keto-PGF1 alpha in patients with acute obstructive suppurative cholangitis]. Miao XY Zhonghua Wai Ke Za Zhi; 1990 Apr; 28(4):228-30, 253-4. PubMed ID: 2379443 [TBL] [Abstract][Full Text] [Related]
12. Effect of OKY-046, a thromboxane A2 synthetase inhibitor, on arachidonate-induced platelet aggregation: possible role of "prostaglandin H2 steal" mechanism. Kuzuya T; Hoshida S; Yamagishi M; Ohmori M; Inoue M; Kamada T; Tada M Jpn Circ J; 1986 Nov; 50(11):1071-8. PubMed ID: 3102802 [TBL] [Abstract][Full Text] [Related]
13. Antithrombotic activity of garlic: its inhibition of the synthesis of thromboxane-B2 during infusion of arachidonic acid and collagen in rabbits. Ali M; Thomson M; Alnaqeeb MA; al-Hassan JM; Khater SH; Gomes SA Prostaglandins Leukot Essent Fatty Acids; 1990 Oct; 41(2):95-9. PubMed ID: 2274570 [TBL] [Abstract][Full Text] [Related]
14. Effect of single-dose aspirin on TXA2 and PGI2 cyclooxygenases in vivo. Zaragoza R; Le Breton GC Haemostasis; 1987; 17(1-2):40-8. PubMed ID: 3110025 [TBL] [Abstract][Full Text] [Related]
15. Protective effects of a new specific thromboxane antagonist in arachidonate-induced sudden death. Lefer DJ; Mentley RK; Lefer AM Arch Int Pharmacodyn Ther; 1987 May; 287(1):89-95. PubMed ID: 2957969 [TBL] [Abstract][Full Text] [Related]
16. Pathophysiological mechanisms of sudden death induced by platelet activating factor. Lefer AM; Müller HF; Smith JB Br J Pharmacol; 1984 Sep; 83(1):125-30. PubMed ID: 6435705 [TBL] [Abstract][Full Text] [Related]
17. In vivo enhancement of platelet activating factor-induced prostacyclin production by OKY-046, a selective inhibitor of thromboxane A2 synthase. Davenport NJ; Goldstein RE; Feuerstein GZ J Cardiovasc Pharmacol; 1991 Apr; 17(4):641-6. PubMed ID: 1711633 [TBL] [Abstract][Full Text] [Related]
18. Thromboxane A2 accounts for bronchoconstriction but not for platelet sequestration and microvascular albumin exchanges induced by fMLP in the guinea pig lung. Bureau MF; De Clerck F; Lefort J; Arreto CD; Vargaftig BB J Pharmacol Exp Ther; 1992 Feb; 260(2):832-40. PubMed ID: 1738127 [TBL] [Abstract][Full Text] [Related]
19. Influence of selective thromboxane synthetase blocker CGS-13080 on thromboxane and prostacyclin biosynthesis in whole blood: evidence for synthesis of prostacyclin by leukocytes from platelet-derived endoperoxides. Mehta J; Mehta P; Lawson DL; Ostrowski N; Brigmon L J Lab Clin Med; 1985 Sep; 106(3):246-52. PubMed ID: 3928780 [TBL] [Abstract][Full Text] [Related]
20. Effects of Y-20811, a long-lasting thromboxane synthetase inhibitor, on thromboxane production and platelet function. Mikashima H; Ochi H; Muramoto Y; Yasuda H; Tsuruta M; Maruyama Y Thromb Res; 1986 Aug; 43(4):455-68. PubMed ID: 3094191 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]